Candel Therapeutics reports sustained immune remodeling beyond two years after prostate cancer treatment
AI Summary- Candel Therapeutics announced new data on aglatimagene besadenovec treatment in localized prostate cancer.
- Immune remodeling remained sustained more than two years after treatment, according to the announcement.
- The data were presented at ASTRO 2026.